Grifols, S.A. (NASDAQ:GRFS - Get Free Report) shares shot up 10.6% on Wednesday . The stock traded as high as $7.88 and last traded at $8.17. 971,785 shares traded hands during mid-day trading, an increase of 27% from the average session volume of 765,705 shares. The stock had previously closed at $7.38.
Analyst Ratings Changes
Separately, Morgan Stanley started coverage on shares of Grifols in a research note on Wednesday, February 12th. They set an "overweight" rating for the company.
Read Our Latest Stock Report on GRFS
Grifols Price Performance
The company's 50 day moving average price is $7.40 and its 200-day moving average price is $8.12. The company has a market capitalization of $5.80 billion, a PE ratio of 7.21 and a beta of 0.40. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11.
Institutional Trading of Grifols
Several institutional investors have recently made changes to their positions in GRFS. R Squared Ltd purchased a new stake in Grifols during the 4th quarter worth $28,000. GAMMA Investing LLC boosted its position in Grifols by 44.5% during the 4th quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company's stock worth $37,000 after purchasing an additional 1,527 shares during the period. Blue Trust Inc. boosted its position in Grifols by 254.0% during the 4th quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company's stock worth $52,000 after purchasing an additional 4,970 shares during the period. Tower Research Capital LLC TRC boosted its position in Grifols by 354.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company's stock worth $60,000 after purchasing an additional 6,335 shares during the period. Finally, First Trust Advisors LP purchased a new stake in Grifols during the 4th quarter worth $75,000.
About Grifols
(
Get Free Report)
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
Read More
Before you consider Grifols, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grifols wasn't on the list.
While Grifols currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
